Nutriband Inc. Issues Corrective Press Release on Initiation of Coverage

ORLANDO, Fla., Nov. 8, 2018 /PRNewswire/ -- Nutriband Inc. (OTCQB: NTRB), a development stage company engaged in the development of pharmaceutical and consumer products which can be taken through a transdermal patch, announced today that the press release issued earlier today concerning the issuance of coverage by Small Cap Consumer Research, LLC was issued in error.  Nutriband has not made any projections or predictions as to the future results of its operations or its stock price and does not endorse any projections or predictions made by others. The statements contained the research report are solely those of Small Cap Consumer Research and do not represent the views of Nutriband.  Further, other analysts and research organizations may have opinions on Nutriband and its stock which are different from those of Small Cap Consumer Research.

About Nutriband Inc.

Nutriband is developing a portfolio of transdermal pharmaceutical and consumer products. The Company believes that the transdermal route of administration has several advantages over pills and injections including avoidance of the gastrointestinal tract and related side effects, convenience due to less frequent dosing, and the elimination of the need for painful injections. The Company's lead product is the Defent abuse deterrent fentanyl transdermal system which is being developed to combat the opioid crisis by deterring the abuse and misuse of fentanyl patches.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company's ability to obtain the necessary financing to develop products and conduct the necessary clinical testing; its ability to develop Defent and any other products, the Company's ability to obtain patent protection in the United States for its abuse technology, its ability obtain Federal Food and Drug Administration clearance to market Defent or any other product it may develop; its ability to manufacture or have manufactured and market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; its ability to generate revenue from its consumer transdermal patches; its ability to evaluate and integrate any acquisitions with our business; changes in its business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized development stage company that does not have a product that can be marketed. Except as required by applicable law, we undertake no obligation to revise or update any of our forward-looking statements in order to reflect any event or circumstance that may arise after the date hereof.

For more information, contact: 

Gareth Sheridan
CEO
Nutriband Inc.
407-880-6810
[email protected] 
www.nutriband.com

SOURCE Nutriband Inc.

Related Links

http://www.nutriband.com